top of page

ImmPACT Bio's CEO on bispecifc CAR-T cells for cancer and autoimmune disease

Sumant Ramachandra describes why ImmPACT's programs target more than one antigen, the case for CD19/CD20 in both oncology and autoimmune, TGF-β programs, and keeping science home in the Los Angeles biotech ecosystem.



Comentarios


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page